[CIS PIDD] [cis-pidd] pneumococcal vaccine strategy in adolescents & adults with immune deficiency

[Bleesing, Jacob]

Stan:

You write: “Our policy has been to vaccinate such patients with 23-valent pneumococcal polysaccharide vaccine.” What is the purpose of this vaccination in such patients – to test his immune response or to provide active protection? If the latter, what makes you think he is going to benefit – given the fact that he has low IgG ELIZA antibodies, recurrent infections and bronchiectasis?

I would just caution in following recommendations from  resources such as ACIP when we are dealing with patients with immunodeficiency disorders or suspected immunodeficiency disorders.

Regards,

JB



From: Boyce, Thomas G., M.D. [mailto:Boyce.Thomas at mayo.edu]
Sent: Thursday, December 05, 2013 3:19 PM
To: CIS-PIDD
Subject: RE: [cis-pidd] pneumococcal vaccine strategy in adolescents & adults with immune deficiency

This is true in adults.  In children, you only need to wait 2 months.

From: bounce-44205117-183824398 at lists.clinimmsoc.org<mailto:bounce-44205117-183824398 at lists.clinimmsoc.org> [mailto:bounce-44205117-183824398 at lists.clinimmsoc.org] On Behalf Of Stan Ress
Sent: Thursday, December 05, 2013 2:11 PM
To: CIS-PIDD
Subject: RE: [cis-pidd] pneumococcal vaccine strategy in adolescents & adults with immune deficiency

Hi Laia,

I’d really like to hear what others think but what I understood from the ACIP statement is that, after PPSV23 vaccination, you need to wait at least one year before giving the 13-valent conjugate vaccine (Prevenar 13).

Regards,

Stan

--
Stanley Ress
Associate Professor of Medicine
Head: Division of Clinical Immunology
Department of Medicine
H47 Old Main Building-room 26
Groote Schuur Hospital and UCT
Observatory 7925
Cape Town
South Africa
TEL:INTERN. + 2721-4066201 or 4066197
FAX:   "    + 2721-(0)865173095
Cell: 0833115482
email: stan.ress at uct.ac.za<mailto:stan.ress at uct.ac.za>


From: Laia Alsina Manrique de Lara [mailto:lalsina at hsjdbcn.org]
Sent: 05 December 2013 09:29 PM
To: CIS-PIDD
Cc: CIS-PIDD
Subject: Re: [cis-pidd] pneumococcal vaccine strategy in adolescents & adults with immune deficiency

OK,
So how bad would it be to administer first Pneumovax23 to complete diagnosis, and if no response is observed, administer Prevenar13 for prophylactic purposes +/- IGRT?

Laia Alsina
Allergy and Clinical Immunology Department,
Hospital Sant Joan de Deu, Barcelona.

El 04/12/2013, a las 21:13, "John Ziegler" <j.ziegler at unsw.edu.au<mailto:j.ziegler at unsw.edu.au>> escribió:
Stan

 PPV23 as primary vaccine is still popular in this setting among my colleagues but I think it's unethical not to give PCV13 first.

John


_________________________
Professor John B. Ziegler, AM
Department of Immunology & Infectious Diseases
Sydney Children's Hospital
High St., Randwick NSW 2031
Australia
T: (02) 93821515
F: + 61 + 2 93821580
E: j.ziegler at unsw.edu.au<mailto:j.ziegler at unsw.edu.au>

On 5 Dec 2013, at 8:06 am, "Stan Ress" <stan.ress at uct.ac.za<mailto:stan.ress at uct.ac.za>> wrote:
Hi all,

I have been referred a 15 year-old patient with extremely severe IgA deficiency, recurrent respiratory infections, & bronchiectasis on CT chest. Her baseline vaccine status revealed low IgG ELIZA antibodies against 4/5 antigens, including S. pneumonia & H. Influenza B. Our policy has been to vaccinate such patients with 23-valent pneumococcal polysaccharide vaccine. However, I saw a reference to ACIP recommendation that children & adults with immune compromising conditions or asplenia, should receive 13-valent conjugate vaccine 1st, followed 8 weeks later by unconjugated PPSV23.

Is this the general current practise?

Thanks.
--
Stanley Ress
Associate Professor of Medicine
Head: Division of Clinical Immunology
Department of Medicine
H47 Old Main Building-room 26
Groote Schuur Hospital and UCT
Observatory 7925
Cape Town
South Africa
TEL:INTERN. + 2721-4066201 or 4066197
FAX:   "    + 2721-(0)865173095
Cell: 0833115482
email: stan.ress at uct.ac.za<mailto:stan.ress at uct.ac.za>

________________________________
UNIVERSITY OF CAPE TOWN

This e-mail is subject to the UCT ICT policies and e-mail disclaimer published on our website at http://www.uct.ac.za/about/policies/emaildisclaimer/ or obtainable from +27 21 650 9111. This e-mail is intended only for the person(s) to whom it is addressed. If the e-mail has reached you in error, please notify the author. If you are not the intended recipient of the e-mail you may not use, disclose, copy, redirect or print the content. If this e-mail is not related to the business of UCT it is sent by the sender in the sender's individual capacity.

---

The CIS-PIDD listserv is supported by:

[Image removed by sender.]
The science & practice of human immunology

P: +1.414.224.8095
E: info at clinimmsoc.org<mailto:info at clinimmsoc.org>

Not a member of CIS? Please visit www.clinimmsoc.org<https://cis.execinc.com/edibo/Signup> to join!

You are currently subscribed to cis-pidd as: j.ziegler at unsw.edu.au<mailto:j.ziegler at unsw.edu.au>.
To unsubscribe click here: http://lm.clinimmsoc.org/u?id=183824805.15fcb3e73d1784a002f4bfafdad280c5&n=T&l=cis-pidd&o=44201035

---

The CIS-PIDD listserv is supported by:

[Image removed by sender.]
The science & practice of human immunology

P: +1.414.224.8095
E: info at clinimmsoc.org<mailto:info at clinimmsoc.org>

Not a member of CIS? Please visit www.clinimmsoc.org<https://cis.execinc.com/edibo/Signup> to join!

You are currently subscribed to cis-pidd as: lalsina at hsjdbcn.org<mailto:lalsina at hsjdbcn.org>.
To unsubscribe click here: http://lm.clinimmsoc.org/u?id=183824379.b100fe2a38d513f306e01a50580e257e&n=T&l=cis-pidd&o=44201076

________________________________
No imprimir aquest correu ajudarà a preservar el medi ambient.
Si vostè no és el destinatari del missatge, o l'ha rebut per error, si us plau notifiqui-ho al remitent i destrueixi el missatge amb tot el seu contingut. Està prohibida la distribució no autoritzada del contingut d'aquest missatge.

No imprimir este correo ayudará a preservar el medio ambiente.
Si usted no es el destinatario del mensaje, o lo ha recibido por error, notifíquelo por favor al remitente y destruya el mensaje con todo su contenido. Está prohibida la distribución no autorizada del contenido de este mensaje.

---

The CIS-PIDD listserv is supported by:

[Image removed by sender.]
The science & practice of human immunology

P: +1.414.224.8095
E: info at clinimmsoc.org<mailto:info at clinimmsoc.org>

Not a member of CIS? Please visit www.clinimmsoc.org<https://cis.execinc.com/edibo/Signup> to join!

You are currently subscribed to cis-pidd as: stan.ress at uct.ac.za<mailto:stan.ress at uct.ac.za>.
To unsubscribe click here: http://lm.clinimmsoc.org/u?id=183824729.985c4c1fc1b701ae5f23bbbaa7fc60d8&n=T&l=cis-pidd&o=44204966
  ­­

---

The CIS-PIDD listserv is supported by:

[Image removed by sender.]
The science & practice of human immunology

P: +1.414.224.8095
E: info at clinimmsoc.org<mailto:info at clinimmsoc.org>

Not a member of CIS? Please visit www.clinimmsoc.org<https://cis.execinc.com/edibo/Signup> to join!

You are currently subscribed to cis-pidd as: stan.ress at uct.ac.za<mailto:stan.ress at uct.ac.za>.
To unsubscribe click here: http://lm.clinimmsoc.org/u?id=183824729.985c4c1fc1b701ae5f23bbbaa7fc60d8&n=T&l=cis-pidd&o=44204966

---

The CIS-PIDD listserv is supported by:

[http://www.clinimmsoc.org/UserFiles/image/cis-pidd-list-logo_v1.jpg]
The science & practice of human immunology

P: +1.414.224.8095
E: info at clinimmsoc.org<mailto:info at clinimmsoc.org>

Not a member of CIS? Please visit www.clinimmsoc.org<https://cis.execinc.com/edibo/Signup> to join!

You are currently subscribed to cis-pidd as: boyce.thomas at mayo.edu<mailto:boyce.thomas at mayo.edu>.
To unsubscribe click here: http://lm.clinimmsoc.org/u?id=183824398.f2b8412bd8ff7bcbcdffccce20d02a5f&n=T&l=cis-pidd&o=44205117

---

The CIS-PIDD listserv is supported by:

[http://www.clinimmsoc.org/UserFiles/image/cis-pidd-list-logo_v1.jpg]
The science & practice of human immunology

P: +1.414.224.8095
E: info at clinimmsoc.org<mailto:info at clinimmsoc.org>

Not a member of CIS? Please visit www.clinimmsoc.org<https://cis.execinc.com/edibo/Signup> to join!

You are currently subscribed to cis-pidd as: jack.bleesing at cchmc.org<mailto:jack.bleesing at cchmc.org>.
To unsubscribe click here: http://lm.clinimmsoc.org/u?id=183824396.60ab2025d9ab67496282f5c977f33e12&n=T&l=cis-pidd&o=44205149

---
The CIS-PIDD listserv is supported by the Clinical Immunology Society
The science & practice of human immunology

P: +1.414.224.8095
E: info at clinimmsoc.org

Not a member of CIS? Please visit www.clinimmsoc.org to join!

You are currently subscribed to cis-pidd as: pagid at list.clinimmsoc.org.
To unsubscribe click here: http://lm.clinimmsoc.org/u?id=183939985.3ea13d40a15475ac00ebbd9cd8a37d6d&n=T&l=cis-pidd&o=44205190
or send a blank email to leave-44205190-183939985.3ea13d40a15475ac00ebbd9cd8a37d6d at lists.clinimmsoc.org
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://seven.pairlist.net/pipermail/pagid/attachments/20131205/759b95f8/attachment.htm>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: not available
Type: image/jpeg
Size: 620 bytes
Desc: image001.jpg
Url : <http://seven.pairlist.net/pipermail/pagid/attachments/20131205/759b95f8/attachment-0001.jpe>